drugset / Trial / NCT06281106

TYK2 Inhibition in Paradoxical Psoriasis

NCT06281106

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Paradoxical psoriasis is a side effect of a biological treatment (anti-tumor necrosis factor agent, short called anti-TNF) that is used to treat diseases of the skin, the intestine or the joints. If paradoxical psoriasis occurs, the anti-TNF-treatment often needs to be stopped and so far, no specific treatment for paradoxical psoriasis exists. This research project aims to study whether the efficacy of the drug 'Deucravacitinib' 6mg, a tablet taken by mouth once a day is superior compared to taking a placebo in treating paradoxical psoriasis.

Timeline

Start
2024-06-20
Primary completion
2025-03-20
Completion
2025-03-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator CRAVACITINIB Small molecule 6 mg Oral

Indications